Bitget Wallet has partnered with RealityFi to offer over 1,700 tokenized US stocks and ETFs directly on-chain, allowing its 100 million users to trade shares like Nvidia, Tesla, and Apple without needing a brokerage account. These tokenized shares, called rTokens, are backed 1:1 by actual stocks held by a FINRA-registered broker and trade during US market hours through real exchanges. Dividends and corporate actions are automatically managed, providing a near-real stock ownership experience within a crypto wallet. However, these tokens are only available to non-US persons under El Salvador’s regulatory framework, excluding American users for now. This move expands access to US equities for users in Asia, Latin America, and Africa, regions where international brokerage access has been limited.
The tokenization of 1,700 US stocks for Bitget Wallet users provides context for digital asset markets. For readers following cryptocurrencies, here is Pluang's market snapshot as of Sep 16, 2026 02:11 WIB: out of 50 major cryptocurrencies priced on Pluang, 5 rose and 44 fell. Notable movers include EOS at Rp12.649 with an 8.13% increase and VET at Rp127 with a 7.89% decrease.
Uber Technologies reported a 25% year-over-year increase in gross bookings to $53.7 billion in Q1 2026, driven by growth in ride-hailing, delivery, grocery, retail, and membership services. CEO Dara Khosrowshahi's recent purchase of 141,000 shares wo...
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
